Download App

Log in to access Online Inquiry
Company Overview More
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Kα inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

RLAY Relay Therapeutics
18.030+0.420+2.39%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
23.7% 898.18M 41.3% 958.07M 41.3% 958.07M -13.59% 616.51M
-Cash and cash equivalents
-54.54% 119.45M -37.42% 280.12M -37.42% 280.12M -59.13% 228.56M
-Short-term investments
68.06% 778.73M 194.23% 677.95M 194.23% 677.95M 151.61% 387.95M
Receivables
-42.53% 4.95M -94.02% 4.94M -94.02% 4.94M -- 5.06M
-Accounts receivable
-- 269K -99.46% 403K -99.46% 403K -- 804K
-Other receivables
-45.65% 4.68M -40.72% 4.54M -40.72% 4.54M -- 4.25M
Prepaid assets
63.33% 12.66M 40.96% 13.23M 40.96% 13.23M 111.07% 17.7M
Total current assets
23.35% 915.79M 26.77% 976.24M 26.77% 976.24M -11.44% 639.26M
Non current assets
Net PPE
4.21% 29.21M -5.22% 27.32M -5.22% 27.32M -5.09% 27.48M
-Gross PPE
4.21% 29.21M 5.92% 41.69M 5.92% 41.69M -5.09% 27.48M
-Accumulated depreciation
-- -- -36.44% -14.37M -36.44% -14.37M -- --
Goodwill and other intangible assets
-- 2.3M -- 2.3M -- 2.3M -- 2.3M
Other non current assets
193.62% 2.58M 186.44% 2.58M 186.44% 2.58M 193.62% 2.58M
Total non current assets
17.91% 34.09M 8.32% 32.2M 8.32% 32.2M 8.46% 32.36M
Total assets
23.15% 949.88M 26.08% 1.01B 26.08% 1.01B -10.65% 671.62M
Liabilities
Current liabilities
Payables
43.98% 8.05M 30.31% 8.28M 30.31% 8.28M 38.72% 6.32M
-accounts payable
43.98% 8.05M 30.31% 8.28M 30.31% 8.28M 38.72% 6.32M
Current accrued expenses
71.61% 15.22M 140.3% 13.37M 140.3% 13.37M 107.67% 20.1M
Current debt and capital lease obligation
18.42% 1.92M 21.24% 1.84M 21.24% 1.84M 23.38% 1.77M
-Current capital lease obligation
18.42% 1.92M 21.24% 1.84M 21.24% 1.84M 23.38% 1.77M
Current deferred liabilities
-- 166K -- 248K -- 248K -- 331K
Other current liabilities
-- 16.33M 196.95% 585K 196.95% 585K -- --
Current liabilities
159.22% 41.69M 78.41% 24.32M 78.41% 24.32M 82.03% 28.52M
Non current liabilities
Long term debt and capital lease obligation
-8.55% 20.56M -8.06% 21.06M -8.06% 21.06M -4.18% 21.55M
-Long term capital lease obligation
-8.55% 20.56M -8.06% 21.06M -8.06% 21.06M -4.18% 21.55M
Restricted common stock
-- -- -- 0 -- 0 -- 0
Other non current liabilities
-- 45.66M -- 65.26M -- 65.26M -- 50.47M
Total non current liabilities
194.6% 66.22M 276.85% 86.31M 276.85% 86.31M 220.19% 72.01M
Total liabilities
179.84% 107.91M 202.81% 110.64M 202.81% 110.64M 163.46% 100.53M
Shareholders'equity
Share capital
21.11% 109K 21.11% 109K 21.11% 109K 2.22% 92K
-common stock
21.11% 109K 21.11% 109K 21.11% 109K 2.22% 92K
-Preferred stock
-- 0 -- 0 -- 0 -- 0
Retained earnings
-85.96% -830.15M -90.02% -768.1M -90.02% -768.1M -59.42% -700.64M
Paid-in capital
42.59% 1.68B 42.79% 1.67B 42.79% 1.67B 10.31% 1.27B
Gains losses not affecting retained earnings
-76916.67% -9.22M -1800% -1.09M -1800% -1.09M -94.32% 10K
Total stockholders'equity
14.9% 841.97M 17.62% 897.81M 17.62% 897.81M -19.96% 571.09M
Total equity
14.9% 841.97M 17.62% 897.81M 17.62% 897.81M -19.96% 571.09M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%